Linked research, clinical, and regulatory source pathways.
Company profile
About OptraSCAN
OptraSCAN is a pioneering digital pathology company dedicated to transforming pathology services through advanced digital slide scanners and AI-driven solutions. The company holds various patents on automatic scanning device technology coupled with tumor and immune cell intelligent scoring systems. OptraSCAN empowers healthcare institutions to transition from traditional microscopes to digital pathology for improved diagnostics, research, and education. The company's comprehensive product portfolio includes multiple whole slide scanner models (OS-Ultra, OS-SiX, OS-Lite, OS-FLi for fluorescence), the IMAGEPath image management system, and AI-powered analytics solutions. Their integrated solutions target specific clinical applications including tuberculosis monitoring (BactoSiA), cervical cancer screening (CytoSiA), and breast cancer analysis (HistoSiA). OptraSCAN's technology offers high-speed precise imaging and analysis that streamlines laboratory workflows, enhancing diagnostic accuracy and improving patient outcomes. The company provides flexible deployment models including traditional capital equipment purchases and innovative on-demand solutions such as pay-per-use scanning, telepathology services, and digital lab-as-a-service offerings. Their IMAGEPath platform enables secure storage, viewing, sharing, and collaboration on whole slide images with HIPAA-compliant cloud or local server options. OptraSCAN serves pathology laboratories, hospitals, research centers, and healthcare institutions globally, supporting both clinical diagnostics and research applications across multiple disease areas including oncology, infectious diseases, and cytology.
Company description OptraSCAN official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at OptraSCAN?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast Cancer
- Cervical Cancer
- Cytology specimens
- General oncology
- Infectious diseases
- Lung Cancer
- Prostate Cancer
- Tuberculosis
Who it serves
- Academic institutions
- Healthcare institutions
- Hospitals
- Pathology laboratories
- Research centers
Deployment & integration
Deployment information is currently being developed.
Recorded integration context: HIS, HL7 interface, LIMS, LIS, PACS, Salesforce AppExchange, Third-party digital pathology scanners.
Geographic context
MarketsAdvanced and emerging economies · Global presence implied through worldwide country selection form · Serving both urban and rural areas
Company sourceOfficial website
Company milestones
Platform expansion
Launch of BactoSiA for TB monitoring and follow-up, Launch of HistoSiA Breast pay-per-use solution, Launch of OS-FS Frozen Section imaging modality, Exhibiting at 115th USCAP Annual Meeting, Attending 12th Digital Pathology and AI Congress Europe (London, Dec 2025), Attending World Health Expo
Partnerships
Recorded partners
- Salesforce AppExchange partnership mentioned
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.Applied immunohistochemistry & molecular morphology : AIMM · Apr 1, 2019
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Improved diagnostic accuracy
Through high-speed precise imaging and AI-driven analysis
Streamlined lab workflows
Enhanced workflow efficiency through digital pathology systems
Improved patient outcomes
Through faster diagnostics and enhanced accuracy
Reduced turnaround time
Built-in tools for accelerated review and reporting
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from OptraSCAN
Recent articles published on OptraSCAN's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.